Home » Stocks » AKTX

Akari Therapeutics, PLC (AKTX)

Stock Price: $1.81 USD -0.05 (-2.69%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $1.83 +0.02 (1.11%) May 7, 7:13 PM
Market Cap 69.64M
Revenue (ttm) n/a
Net Income (ttm) -17.08M
Shares Out 3.16B
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $1.81
Previous Close $1.86
Change ($) -0.05
Change (%) -2.69%
Day's Open 1.87
Day's Range 1.78 - 1.94
Day's Volume 691,732
52-Week Range 1.42 - 4.21

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The FDA has granted Fast Track designation to Akari Therapeutics Plc's (NASDAQ: AKTX) nomacopan to treat patients with moderate and severe Bullous Pemphigoid (BP). Nomacopan has also been granted orphan...

1 week ago - Benzinga

NEW YORK and LONDON, April 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory...

2 weeks ago - GlobeNewsWire

NEW YORK and LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and i...

2 weeks ago - GlobeNewsWire

The FDA has opened the investigational new drug application for Phase 3 trial for Akari Therapeutics Plc's (NASDAQ: AKTX) lead drug candidate, nomacopan, for the treatment of moderate and severe Bullous...

3 weeks ago - Benzinga

FDA investigational new drug application (IND) now open

3 weeks ago - GlobeNewsWire

Study of porcine model of blast injury and haemorrhagic shock underway with USAISR as part of the development of a clinical path for the use of nomacopan to treat trauma Study of porcine model of blast ...

2 months ago - GlobeNewsWire

Akari Therapeutics Plc (NASDAQ: AKTX) announces new data from PASylated nomacopan published in the journal CELLS. In a non-infectious allergic uveitis animal model, PAS-nomacopan reduced VEGF by more th...

2 months ago - Benzinga

NEW YORK and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

2 months ago - GlobeNewsWire

NEW YORK and LONDON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

3 months ago - GlobeNewsWire

NEW YORK and LONDON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

4 months ago - GlobeNewsWire

NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

4 months ago - GlobeNewsWire

NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and in...

4 months ago - GlobeNewsWire

NEW YORK and LONDON, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory ...

5 months ago - GlobeNewsWire

NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory ...

6 months ago - GlobeNewsWire

NEW YORK and LONDON, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory ...

7 months ago - GlobeNewsWire

NEW YORK and LONDON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory ...

7 months ago - GlobeNewsWire

NEW YORK and LONDON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...

7 months ago - GlobeNewsWire

NEW YORK and LONDON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and...

8 months ago - GlobeNewsWire

NEW YORK and LONDON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a Phase III biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and ...

8 months ago - GlobeNewsWire

NEW YORK and LONDON, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammator...

8 months ago - GlobeNewsWire

NEW YORK and LONDON, July 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of...

10 months ago - GlobeNewsWire

NEW YORK and LONDON, July 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of...

10 months ago - GlobeNewsWire

NEW YORK and LONDON, May 29, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory...

11 months ago - GlobeNewsWire

NEW YORK and LONDON, May 21, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory...

11 months ago - GlobeNewsWire

NEW YORK and LONDON, May 01, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory...

1 year ago - GlobeNewsWire

NEW YORK and LONDON, March 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammato...

1 year ago - GlobeNewsWire

NEW YORK and LONDON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammator...

1 year ago - GlobeNewsWire

NEW YORK and LONDON, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat autoimmune and inflammatory disea...

1 year ago - GlobeNewsWire

All patients treated with nomacopan have achieved the primary endpoint of transfusion independence All patients treated with nomacopan have achieved the primary endpoint of transfusion independence

1 year ago - GlobeNewsWire

NEW YORK and LONDON, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq:AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory...

1 year ago - GlobeNewsWire

NEW YORK and LONDON, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammator...

1 year ago - GlobeNewsWire

NEW YORK and LONDON, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammator...

1 year ago - GlobeNewsWire

NEW YORK and LONDON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammato...

1 year ago - GlobeNewsWire

The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.

1 year ago - Zacks Investment Research

NEW YORK and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammato...

1 year ago - GlobeNewsWire

NEW YORK and LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammato...

1 year ago - GlobeNewsWire

The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.

1 year ago - Zacks Investment Research

Akari Therapeutics PLC (NASDAQ: AKTX) shares are on track to reclaim the $2 level for the first time since mid-August thanks to two doses of positive tidings from the company.

1 year ago - Benzinga

Akari Therapeutics PLC shares AKTX, +12.21% soared 13% in premarket trade Friday, after the company said it has won U.S.

1 year ago - Market Watch

NEW YORK and LONDON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammator...

1 year ago - GlobeNewsWire

- Positive early safety and efficacy data with nomacopan

1 year ago - GlobeNewsWire

Some recent biopharma news concerning Akari Therapeutics getting Fast Track approval from the FDA has AKTX stock flying high on Wednesday. The post Biopharma News: Why Akari Therapeutics (AKTX) Stock I...

1 year ago - InvestorPlace

The thinly traded, nano-cap biotech Akari Therapeutics PLC (NASDAQ: AKTX) gap-opened higher Wednesday morning, and shares were advancing strongly on above-average volume.

1 year ago - Benzinga

Akari Therapeutics PLC (NASDAQ: AKTX) shares jumped on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its stem cell transplant...

1 year ago - 24/7 Wall Street

Shares of Akari Therapeutics PLC rocketed 61% to pace all premarket gainers in very active trading Wednesday, after the biopharmaceutical company said its treatment (nomacopan) of stem-cell transplant a...

1 year ago - Market Watch

Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.

1 year ago - Zacks Investment Research

Shares of Akari Therapeutics PLC (NASDAQ: AKTX)  were soaring Wednesday.

1 year ago - Benzinga

Akari announced positive results from its phase 2 study using Coversin to treat patients with bullous pemphigoid.

2 years ago - Seeking Alpha

Akari Therapeutics PLC (NASDAQ: AKTX) shares were surging Tuesday, breaking above the $4 barrier for the first time in about a month.

2 years ago - Benzinga

Akari Therapeutics PLC shares were surging by more than 150 percent Wednesday after reporting a positive meeting with the FDA.

2 years ago - Benzinga

About AKTX

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pem... [Read more...]

Industry
Biotechnology
CEO
David Solomon
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
AKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for AKTX stock is "Strong Buy" and the 12-month stock price forecast is 5.00.

Price Target
$5.00
Analyst Consensus: Strong Buy